1. CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy
   Silvio E. Perea et al, 2015, Protein Kinase CK2 Cellular Function in Normal and Disease States CrossRef
2. Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins
   Takashi Takeda et al, 2019, Cell Death & Disease CrossRef
3. The Combination of the CIGB-300 Anticancer Peptide and Cisplatin Modulates Proteins Related to Cell Survival, DNA Repair and Metastasis in a Lung Cancer Cell Line Model
   Arielis Rodríguez-Ulloa et al, 2019, Current Proteomics CrossRef
4. CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
   Janeen H. Trembley et al, 2021, Biomedicines CrossRef
5. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target
   Melissa Chua et al, 2017, Pharmaceuticals CrossRef
6. Role of protein kinase CK2 in antitumor drug resistance
   Christian Borgo et al, 2019, Journal of Experimental & Clinical Cancer Research CrossRef
7. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects
   Sofia Zanin et al, 2015, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics CrossRef
8. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells
   Adam J. Rabalski et al, 2016, Clinical Cancer Research CrossRef
9. Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise
   Janeen H. Trembley et al, 2023, Molecular and Cellular Biochemistry CrossRef
10. Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy
    Mark F. McCarty et al, 2020, Medical Hypotheses CrossRef
11. Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway
    Yonghong Man et al, 2016, Oncology Letters CrossRef
12. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation
    Silvio E. Perea et al, 2018, Seminars in Oncology CrossRef
13. CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
    Ailyn C. Ramón et al, 2022, Viruses CrossRef
14. Molecules that target nucleophosmin for cancer treatment: an update
    Adele Di Matteo et al, 2016, Oncotarget CrossRef
15. Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair
    David J. López et al, 2020, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics CrossRef
16. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
    Mauro Rosales et al, 2021, Cells CrossRef
17. CEP131 indicates poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma
    Xu-Hui Liu et al, 2017, The International Journal of Biochemistry & Cell Biology CrossRef
18. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
    Ailyn C. Ramón et al, 2022, Viruses CrossRef
19. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
    null null et al, 2015, British Journal of Cancer CrossRef
20. Casein kinases as potential therapeutic targets
    Giorgio Cozza et al, 2016, Expert Opinion on Therapeutic Targets CrossRef